How to Evaluate Teeth Whitening Strips for Private Label Production

What Determines Whitening Strip Effectiveness?

A whitening strip is a delivery system, not just a chemical. Effectiveness depends on how much active ingredient reaches the enamel surface, how long it stays in contact, and how consistently the finished formula performs across a full production run — not only on the concentration stated on a spec sheet. A formula with strong actives but poor adhesion, an unstable gel matrix, or unreliable batch-to-batch quality can underperform a more modest formula that was engineered and validated as a complete system.

Active Routes: HP, CP, PAP, and Sodium Chlorite

Among peroxide-based whitening systems, hydrogen peroxide (HP) and carbamide peroxide (CP) are the two most established active routes. HP acts directly; CP breaks down gradually into hydrogen peroxide once in contact with saliva and enamel, so a CP formula releases its active peroxide more slowly over the wear period than an HP formula at the same labeled percentage.

Peroxide-free strips use different chemistry entirely and should be evaluated on their own terms:

• PAP (Phthalimidoperoxycaproic acid) is an alternative oxidative whitening route, marketed as peroxide-free. Its performance and safety profile depends on its own concentration, pH, and formulation — it should not be benchmarked against HP/CP percentages as if they were interchangeable.
• Sodium chlorite strips rely on a different oxidation mechanism and require their own evaluation of concentration, pH, stability, and use conditions; sodium chlorite chemistry behaves differently in storage and in the mouth than either peroxide route.

The practical takeaway for buyers: different active routes cannot be compared on percentage alone. A formula evaluation request should specify which active system is being assessed, since the relevant test methods, stability behavior, and claim substantiation differ by route.

Concentration and Regulatory Context

Regulatory limits vary by market and directly shape what a formula can be sold as, where.

In the European Union, tooth-whitening products containing or releasing up to 0.1% hydrogen peroxide may be supplied directly to consumers. Products containing or releasing more than 0.1% and up to 6% are restricted to dental-professional channels, with first use performed by, or under the direct supervision of, a dental practitioner.

In the United States, there is no single federal peroxide concentration limit applied uniformly to every OTC whitening product. Brands are instead required to substantiate product safety, efficacy, and labeling claims. Review programs such as the ADA Seal of Acceptance evaluate the finished product against its supporting laboratory and clinical evidence — including active ingredient measurement, enamel surface microhardness, erosion testing, and clinical data — rather than certifying products against one standard concentration.

Buyers should request the actual active ingredient percentage for the specific active route in use, and confirm which regulatory framework applies to the intended sales market, rather than assuming one concentration threshold applies globally.

Contact Time Is Formula-Specific, Not a Fixed Standard

Commercial whitening-strip protocols vary widely across the market — published and commercial products span a wide range of active concentrations and wear regimens, and there is no single wear-time standard that applies to every formula. The correct wear time has to be established for the specific finished formula, active concentration, gel loading, and strip design — it isn't a fixed industry number that can be assumed from the active percentage alone.

The core principle for evaluation is: concentration and wear time must be assessed together, as they were validated together by the manufacturer — not treated as independently interchangeable variables.

Strip Adhesion and Film Substrate

The polymer film that carries the whitening gel determines how evenly the active ingredient stays in contact with enamel. Key factors include:

• Substrate flexibility — the film needs to conform to the arch and interproximal spaces without gapping, since gaps create uneven whitening.
• Gel viscosity and tack — gel that's too thin can migrate off the tooth surface; gel that's too thick may fail to reach contact areas.
• Edge and seal design — poor edge control or excessive gel migration can increase soft-tissue contact and may contribute to gingival irritation, though irritation is a multi-factor outcome and edge design is one contributing variable among several (see Sensitivity Risk Management below).

A manufacturer should be able to provide adhesion or wear-retention test data — not just a qualitative description of the film — on request.

Formula Stability: Broader Than Shelf-Life Percentage

Hydrogen peroxide and other oxidative actives degrade over time, particularly with heat, light, and moisture exposure. Accelerated stability testing may use elevated temperature and humidity conditions — such as 40°C/75% relative humidity — but the specific protocol should be justified for the product, its packaging, and its target market, and supported by real-time stability data rather than accelerated data alone.

A complete stability evaluation covers more than remaining active concentration over time. Buyers should also ask about:

• Active ingredient concentration at defined intervals against real-time and accelerated data
• pH stability over the shelf-life period
• Gel viscosity consistency
• Film-gel delamination or separation risk
• Pouch/blister seal integrity
• Odor, color, and taste change
• Microbial quality
• Packaging material compatibility with the formula

Request a stability data package covering these points for the actual finished packaging configuration — not a stated shelf-life claim alone.

Sensitivity Risk Management

Tooth sensitivity and gum irritation are among the most commonly reported, generally temporary effects of tooth-whitening products, influenced by concentration, contact time, use frequency, individual tooth condition, and the complete formula — not any single variable in isolation. Formulas designed to reduce sensitivity risk may include:

• Potassium nitrate, which is commonly used to reduce nerve excitability in dentinal tubules.
• Amorphous calcium phosphate (ACP) or fluoride, used to support enamel remineralization during and after the whitening cycle.
• pH buffering, since formula pH can affect enamel demineralization risk.

Desensitizing ingredients may support a sensitivity-conscious formula, but their inclusion does not on its own justify claims such as "zero sensitivity" or "no irritation" unless the finished product has clinical or consumer evidence to support that specific claim.

Testing and Validation Methods

A formula claim is only as credible as the testing behind it. When evaluating a manufacturer, ask which of the following they can produce:

1. In vitro shade testing — enamel samples measured with a spectrophotometer (ΔE shade change) before and after a simulated wear protocol, giving objective, repeatable efficacy data.
2. Finished-product potency testing — a validated assay (an appropriate titration, chromatographic method, or another method validated for the specific active) confirming that each released batch meets its approved concentration specification. The method should be matched to the active in use; a validated method with a defined acceptance range and batch traceability matters more than which specific instrument is used.
3. Stability testing — as outlined above, run on the actual finished packaging.
4. Consumer or clinical panel testing — shade change and sensitivity self-reporting over the full use protocol, ideally with a defined sample size and standardized before/after documentation.

A manufacturer with in vitro and finished-product potency data available is a materially stronger sourcing partner than one relying only on raw-material certificates or marketing claims.

Batch-to-Batch Consistency

A sample formula that performs well in evaluation does not guarantee that every production batch will perform the same way. This is one of the most overlooked evaluation steps for private label buyers, and one of the most common sources of post-launch complaints when it's skipped. Batch consistency checkpoints to request from a manufacturer include:

• Gel loading per strip
• Active concentration release range (acceptance tolerance, not a single target number)
• Strip dimensions and film thickness
• Gel coating uniformity across the strip
• Individual pouch seal strength
• Net weight tolerance
• Batch coding and traceability
• Certificate of Analysis (COA) per batch
• Retained samples policy
• Change-control procedure for any formula, supplier, or process modification

A manufacturer that can walk through these checkpoints — and provide a COA per batch as standard practice — is set up for consistent production, not just a strong sample.

Formula Claims and Evidence

Marketing claims should be tied to the specific evidence that supports them. This mapping is worth confirming with a manufacturer before finalizing packaging copy:

Any claim without a corresponding evidence type on hand is a labeling risk for the brand, not just a manufacturing detail — the brand carries the regulatory and reputational exposure, not the factory.

Formulation Evaluation Checklist for Private Label and OEM Buyers

Before tooling or packaging decisions, request the following from a manufacturer:

• Confirmed active route (HP, CP, PAP, sodium chlorite, or other) and finished-product concentration
• Wear time and duration protocol specific to that formula, with supporting rationale
• Film substrate and adhesion/wear-retention test data
• Full stability data package for the intended shelf life and packaging format
• Desensitizing agent inclusion and rate, if applicable
• Available in vitro shade-change and finished-product potency test reports
• Batch-to-batch consistency data and COA practices
• Regulatory compliance mapping to the target sales market
• Evidence on file for each intended marketing claim

Sourcing a whitening strip formula for private label production means evaluating the complete system — active route, dosing, delivery, stability, and batch consistency — and confirming the evidence behind any claim the brand intends to make. Buyers who request this documentation upfront, across HP, CP, PAP, or sodium chlorite formats, avoid the most common cause of underperforming private label launches: a formula that reads well on a spec sheet but wasn't engineered, or validated, as a complete system.